Jacobs Levy Equity Management
BCAB icon

Jacobs Levy Equity Management’s BioAtla BCAB Stock Holding History

Jacobs Levy Equity Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,962
Closed -$383K – 1078
2024
Q4 		$383K Buy
+12,962
New +$1.09M ﹤0.01% 847

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Jacobs Levy Equity Management's BCAB Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of BioAtla (BCAB) in Q1 2025, closing a stake of 12,962 shares — an estimated $383K sold.

Jacobs Levy Equity Management first reported a position in BCAB in Q4 2024 and held it in 1 quarter. The position peaked at $383K in Q4 2024. 41 funds tracked by Wall St. Rank hold BCAB as of Q1 2025.

  • Jacobs Levy Equity Management reported no remaining BioAtla position as of Q1 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 12,962 BioAtla shares in Q1 2025, an estimated $383K.
  • Jacobs Levy Equity Management first reported a position in BioAtla in Q4 2024 and held it in 1 quarter.
  • Jacobs Levy Equity Management's BioAtla position peaked at $383K in Q4 2024.
  • 41 funds tracked by Wall St. Rank held BioAtla as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.